Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Generic Drugs FDA Cancer

Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates

  • News

Executive Summary

Under the Oncology Center of Excellence’s Project Renewal, agency has contracted with consulting firm Deloitte to establish subject matter expert research teams that will review published literature on off-patent drugs and suggest labeling updates.


Table

View full table

Advertisement

Related Content

Pink Sheet
Generic Labeling Problems Targeted In US FDA Budget Request
Pink Sheet
Generic Labeling Problems Targeted In US FDA Budget Request
Pink Sheet
Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates
Pink Sheet
Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates
Pink Sheet
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
Pink Sheet
US FDA Wins Big In Shutdown-Averting Approps Bill
Pink Sheet
Project Renewal: US FDA's Plan To Update Generic Cancer Drug Labels Depends On NDA Holders
Pink Sheet
US FDA's Label Updating Effort Needs Legislation To Impact Generics
Pink Sheet
US FDA Looks To Proactively Update Old Generic Drug Labels Under Pilot
Pink Sheet
Labeling Updates For Old Drugs Could Be Faster Under Streamlining Proposal

Topics

Advertisement
Tags:
Generic Drugs FDA Cancer
UsernamePublicRestriction

Register

PS125059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By